- Oops!Something went wrong.Please try again later.
Shares of Alzheimer's disease drug developer Cassava Sciences (NASDAQ: SAVA) have soared this year thanks to progress with a potential new drug called sumifilam. Does simufilam have a clear enough shot at success to make Cassava Sciences a smart investment right now? Cassava Sciencesa's lead candidate, sumifilam is a potential new dementia treatment that restores the shape and function of an important structural protein found in the brain called filamin A. Last November, Cassava sciences reported clinical trial results for sumifilam that suggest stabilizing this protein has an important knock-on effect.